ACCESSIBILITY

24/7

Headlines

18:25

Tomorrow.io raises $175 million at over $1 billion valuation to build AI-driven weather satellite network

15:30

Cyber startup Orion raises $32 million Series A backed by IBM for AI-driven data-leak prevention

15:08

Full list of Israeli startup M&As in 2026

15:05

Medtronic to acquire Israeli AI cardiology firm CathWorks for $585 million, deal could reach $1 billion

Buzz

Most popular

Daily

Weekly

Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”

Israeli defense firms target Asia as Singapore Airshow opens amid regional arms race

After $400M cyber exit, ex-IntSights CEO raises $11M to build AI app for personalized sports highlights

Medtronic to acquire Israeli AI cardiology firm CathWorks for $585 million, deal could reach $1 billion

Why Apple paid billions for a company with no revenue

More news

Pharma

13 stories about Pharma

Israeli Pharma Company Wavelength Appoints New CEO

30.11.17|CTech

Pharma veteran Iftach Seri was named as Wavelength’s CEO. Formerly a Perrigo subsidiary, the company was recently sold to New York-based investment firm SK Capital for $110 million

Teva Announces Restructuring, Ousts Second in Command

27.11.17|Golan Hazani

The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich

Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich

Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer

Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer

Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich

Troubled drugmaker says new CEO must work to quickly regain its financial credibility

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich

The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani

Sol-Gel approached potential underwriters. It aims to go public before the end of the year

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani

The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian

The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016

Teva’s Perfect Storm Sends Tel-Aviv Stock Exchange Down

06.08.17|Calcalist

Teva’s stock price dropped sharply on Thursday and Friday after the company released quarterly revenue and profits that fell short of analysts’ forecasts